Daiichi Sankyo selling API plant; GSK pays EPA fine; Ebola vax maker lines up contract manufacturers;

> Japan's Daiichi Sankyo will sell an API plant to Alfresa Pharma, but then continue to manufacture products in it. Release

> Northern Ireland-based contract development and manufacturing group Almac will receive incentives of about £5.5 million from the country for investing £54 million and creating 348 jobs over the next 5 years. Release

> GlaxoSmithKline ($GSK) has agreed to pay to pay a $317,550 penalty to settle with the EPA alleged hazardous waste violations tied to a waste ethanol storage tank at its R&D facility in King of Prussia, PA. Release

> A new report says high potency active pharmaceutical ingredients (HPAPIs) and cytotoxic drugs should provide opportunities for contract manufacturers. Report

> New York Senator Charles Schumer says he asked the FDA to ask manufacturers to produce more doxycycline to bring down the price. Story

And Finally... NewLink Genetics,which has licensed the Ebola vaccine developed by Canadian government scientists, says it has at least two contract manufacturing companies which can produce tens of thousands of vaccine doses within two months. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.